
|Videos|April 19, 2022
Potential Implications of the REFINE Trial on the Myelofibrosis Treatment Paradigm
Author(s)Naveen Pemmaraju, MD
Naveen Pemmaraju, MD, talks about the potential implications of the phase II REFINE trial on the myelofibrosis treatment paradigm.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5

















